Mankind Pharma Q2 Net Profit Surges 29%, Beats Forecasts

resr 5paisa Research Team

Last Updated: 5th November 2024 - 05:38 pm

Listen icon

Mankind Pharma Ltd. reported a 29% increase in consolidated net profit for the second quarter of fiscal 2025, surpassing analysts' expectations. The company recorded a net profit of ₹658.88 crore for the quarter ending September 30, 2024, up from ₹473 crore in the same period last year, as per a filing on Tuesday. Bloomberg-tracked analysts had projected a profit of ₹600 crore. 

Mankind Pharma Q2 Results Highlights

  • Revenue: Up 13.6% to ₹3,076.51 crore versus ₹2,708.10 crore.
  • Net Profit: Up 29% to ₹658.88 crore versus ₹511.18 crore.
  • EBITDA: Up 25% to ₹850.04 crore versus ₹682.65 crore. Margin at 27.6% versus 25.2%.
  • Market Reaction: Shares closed 0.62% lower on Tuesday, as against a 0.91% advance in the benchmark Nifty 50. 

Stock Market Reaction

Mankind Pharma stock price closed 0.62% lower on Tuesday, as against a 0.91% advance in the benchmark Nifty 50.

About Mankind Pharma

Mankind Pharma Limited is a pharmaceutical company that specializes in the development, production, and marketing of a wide array of pharmaceutical formulations. These formulations address both acute and chronic therapeutic needs. Additionally, the company offers a variety of consumer healthcare products and primarily serves the Indian market. 

FREE Trading & Demat Account
Open FREE Demat Account with endless opportunities.
  • Flat ₹20 Brokerage
  • Next-gen Trading
  • Advance Charting
  • Actionable Ideas
+91
''
By proceeding, you agree to our T&Cs*
Mobile No. belongs to
hero_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form